Subtype
Bladder Neoplasm
CI-CAN-00001978Explore in graph →
Non-malignant390 active trials10 approved drugs25 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001978Explore in graph →
Clinical trials
1,702 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05679557 | Comprehensive Geriatric Assessment for Perioperative Optimization in Cystectomy(COMPETENCE) | recruiting | N/A | 140 | Aarhus University HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07424560 | Multiplex Mutation Detection Using Mass Spectrometry in Bladder Cancer | recruiting | — | 400 | Zhilong DongOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT04848519 | Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma | active not recruiting | Phase 2 | 6 | Emory UniversityOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06470282 | Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer | recruiting | Phase 1 / Phase 2 | 47 | University of California, San FranciscoOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07030257 | Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | Tasca TherapeuticsINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors(EBNK-ST-001) | recruiting | Phase 1 / Phase 2 | 83 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03520491 | A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy | active not recruiting | Phase 2 | 52 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06138561 | Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments | recruiting | — | 180 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07234968 | Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy | recruiting | N/A | 70 | Thomas Jefferson UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07403630 | INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)(IT-TCP POS) | recruiting | N/A | 300 | Azienda Ospedaliero-Universitaria di ParmaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06778863 | A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation(GUARDIAN-101) | recruiting | Phase 1 | 90 | Clasp Therapeutics, Inc.INDUSTRY | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07408830 | VA Randomized Trial of Surveillance Intervals After Transurethral Resection of High Grade Bladder Tumors(VATSIT) | not yet recruiting | N/A | 2,482 | VA Office of Research and DevelopmentFED | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06764095 | Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial | recruiting | Phase 4 | 75 | Mayo ClinicOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07008833 | Radical CystEctomy or RaDio-chEMotherapy as Preferred Treatment for invasivE blaDder Cancer(REDEMPTED) | not yet recruiting | N/A | 336 | Brazilian Clinical Research InstituteOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04368702 | CONFIRM: Magnetic Resonance Guided Radiation Therapy(CONFIRM) | recruiting | N/A | 70 | Brigham and Women's HospitalOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07395037 | A Study of Ward Admissions for Haematuria(WASHOUT) | recruiting | — | 1,050 | British Urology Researchers in Surgical TrainingOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT03740256 | Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors(VISTA) | recruiting | Phase 1 | 45 | Baylor College of MedicineOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04459273 | Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers(FAPI PET RDRC) | active not recruiting | Phase 1 | 26 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04916990 | Improving Care for Rural Patients With Solid Tumors | recruiting | N/A | 320 | University of Colorado, DenverOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03193515 | A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer | recruiting | — | 300 | Cedars-Sinai Medical CenterOTHER | 2 | Feb 4, 2026 | clinicaltrials |
| NCT03193528 | A Novel Multiplex ELISA Assay for Evaluating Patients With Gross Hematuria for Bladder Cancer | active not recruiting | — | 450 | Cedars-Sinai Medical CenterOTHER | 2 | Feb 4, 2026 | clinicaltrials |
| NCT03193541 | A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer | recruiting | — | 900 | Cedars-Sinai Medical CenterOTHER | 2 | Feb 4, 2026 | clinicaltrials |
| NCT05347342 | A Diagnostic for the Early Detection of Bladder Cancer | active not recruiting | — | 173 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07379255 | Evaluation of Postoperative Adjuvant Chemotherapy Efficacy for Bladder Cancer Based on Organoid Technology. | recruiting | — | 266 | Qilu Hospital of Shandong UniversityOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07379268 | Evaluation of the Efficacy of Anti-HER2 Antibody-Drug Conjugates (ADC) in Locally Advanced or Metastatic Bladder Cancer Based on Organoid Technology. | recruiting | — | 224 | Qilu Hospital of Shandong UniversityOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07379281 | Evaluating the Efficacy of Neoadjuvant Chemotherapy Drugs Based on Organoid Technology | recruiting | — | 254 | Qilu Hospital of Shandong UniversityOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT02432963 | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | active not recruiting | Phase 1 | 11 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06818136 | Bladder EpiCheck European Haematuria Study | recruiting | — | 800 | Nucleix Ltd.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07359235 | Safety, Tolerability, and Preliminary Efficacy of KD01 Via Intravesical Instillation in Bladder Cancer (BC) | recruiting | Phase 1 | 29 | Tongji HospitalOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04630730 | Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC | active not recruiting | Phase 2 | 46 | Swiss Cancer InstituteOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05366881 | cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease(CAMPERR) | recruiting | — | 7,000 | Adela, IncINDUSTRY | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05264337 | Lymphedema After Urologic Surgery | recruiting | — | 400 | Vastra Gotaland RegionOTHER_GOV | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07346053 | The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer(Chrono-EVP) | not yet recruiting | Phase 3 | 224 | Guliz OzgunOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07339761 | Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study(SPICE) | recruiting | N/A | 30 | University of AarhusOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06305767 | A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) | active not recruiting | Phase 1 / Phase 2 | 230 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Jan 13, 2026 | clinicaltrials |
| NCT05544552 | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations(SURF301) | active not recruiting | Phase 1 / Phase 2 | 310 | Tyra Biosciences, IncINDUSTRY | 4 | Jan 12, 2026 | clinicaltrials |
| NCT05656235 | Renal Retention in High Grade Upper Tract Urothelial Cancer | recruiting | Phase 2 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05779631 | Multi-parametric MRI in Patients Suspected for Muscle Invasive Bladder Cancer: a New Local Staging Paradigm(BladParadigm) | recruiting | N/A | 360 | Radboud University Medical CenterOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT00871754 | Molecular Analysis Of Bladder Cancer | active not recruiting | — | 5,000 | Lahey ClinicOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT02989584 | A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer | active not recruiting | Phase 1 / Phase 2 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03171025 | Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer(NEXT) | active not recruiting | Phase 2 | 200 | University of UtahOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07324798 | Adaptive Radiotherapy for Genitourinary Cancers(SMART-B01) | recruiting | N/A | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06870253 | Evaluating Bladder CARE™, a New Non-Invasive Urine Test, for Bladder Cancer Detection in Inconclusive Cases | active not recruiting | — | 80 | Pangea Laboratory LLCINDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05962541 | Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)(CUT-less) | recruiting | Phase 4 | 327 | University of Roma La SapienzaOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06645808 | PET-imaging of Two Vartumabs in Patients With Solid Tumors(VARTUTRACE) | recruiting | Early Phase 1 | 32 | Var2 PharmaceuticalsINDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT05519878 | Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers | recruiting | N/A | 224 | City of Hope Medical CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06022029 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.(ON-5001) | recruiting | Phase 1 | 168 | OncoNano Medicine, Inc.INDUSTRY | 2 | Dec 24, 2025 | clinicaltrials |
| NCT07279597 | A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer | not yet recruiting | Phase 2 | 45 | Tongji HospitalOTHER | 0 | Dec 19, 2025 | clinicaltrials |
| NCT02660645 | Blue Light Cystoscopy With Cysview® Registry(BLCCR) | recruiting | — | 4,400 | PhotocureINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT02993900 | Image-Guided Gynecologic Brachytherapy | recruiting | N/A | 54 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 18, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 27, 2026source: clinicaltrials